세계의 확장성 심근병증(DCM) 치료제 시장 : 치료 접근별, 투여 경로별, 유통 채널별, 지역별 - 기회 및 예측(2018-2032년)

Global canine dilated cardiomyopathy drugs market is projected to witness a CAGR of 5.01% during the forecast period 2025-2032, growing from USD 3.99 billion in 2024 to USD 5.90 billion in 2032. The global canine dilated cardiomyopathy drugs market is experiencing significant growth due to advancements in canine drugs, increased awareness among pet owners, and growing demand for canine DCM treatment.

The market is witnessing a steady increase due to a rise in public awareness, along with advancements in diagnosis and an increasing prevalence of heart disease in dogs, particularly in large and giant breeds. Canine DCM is a severe heart muscle disease, and the main selected drug classes include vasodilators such as pimobendan, diuretics, and angiotension-converting enzyme (ACE) inhibitors to help improve cardiac output and function, relieve fluid retention, and reduce workload on the heart. With regards to the development and growth of the market, research and product development in Canine DCM is ongoing, and the market is analyzing many new treatment options, including genetic therapies and more advanced formulations to produce better and potentially disease-modifying therapies. The market for canine DCM drugs globally is also impacted by a larger phenomenon, which is pet humanization.

Additionally, to oversee the growing pet humanization trends Food and Drug Administration (FDA) also supports by giving approvals of new treatment plans. For instance, in April 2024, Pimomedin chewable tablets, the first generic pimobendane, received approval from the FDA for the management of congestive heart failure in dogs. These drugs help to strengthen the muscular contraction of the heart and widen the blood vessels in these organs.

Rising Prevalence of Canine DCM Drugs Drives Global Market Demand

Medical professionals in veterinary medicine face a rising need for specialized drugs to treat canine dilated cardiomyopathy because it represents a major veterinary medical problem. Dogs of large and giant breeds face the highest DCM risk because the disease primarily affects Dobermans, Great Danes, and Irish Wolfhounds. The condition's appearance in various dog breeds lately has led to inquiries about how diet choices, especially boutique and grain-free options that lack taurine, could be related to the problem. Modern diagnostic tools that include echocardiography and Holter monitoring provide better means to identify this condition. The general increase in pet ownership, along with growing public knowledge brought by social media platforms, together with obvious clinical symptoms of lethargy and coughing, and labored breathing, has led to an increasing number of reported cases of canine DCM.

For instance, in July 2024, Elanco Animal Health Incorporated announced a partnership with The Veterinary Cooperative (TVC) for an extensive portfolio of innovative products and practice resources and enhance the quality of care provided by TVC members.

The Rising Focus on Canine DCM Drug Innovation Drives Market Growth

The global market is undergoing substantial expansion owing to mounting pet populations and better awareness about dog cardiovascular conditions, along with veterinary medical advancements. Multiple pharmaceutical firms, along with research organizations, dedicate their resources to developing new medications that will enhance dog survival and quality of life by addressing DCM as a primary heart failure trigger among large canine breeds. The market surge stems from an increasing requirement for specialized pet care services and the establishment of strategic research partnerships between veterinary health organizations and expanding awareness about pets' benefits on human psychological health. Veterinary pharmaceutical and pet care industry stakeholders can find valuable information about emerging drug developments, together with market dynamics and economic effects of canine DCM treatments.

For instance, in February 2025, Mars Petcare's Waltham Petcare Science Institute launched a program to understand the human-animal bond shared benefits on National Love Your Pet Day. This study also aims to increase awareness of the role played by pets in maintaining owners' mental well-being.

Advances in Veterinary Medicine Drive the Canine Dilated Cardiomyopathy Drugs Market Demand

Progress in veterinary medicine has exponentially enhanced the ability to diagnose and treat canine DCM, increasing demand for canine drug products. Technology advancements such as high-resolution ECG and portable Holter monitor permit earlier diagnosis and continuous monitoring of the heart. Therapeutically, the development of novel drug formulation and delivery methods has improved efficacy and ease of use. Concerning ongoing treatment, telemedicine and digital monitoring systems have helped follow-up care more frequently and constantly than before, facilitating long-term disease management and reinforcing the critical role of veterinary medicine in DCM.

Additionally, to support the digitalization system in September 2023, iRhythm Technologies, Inc. introduced its next-generation Zio monitor and enhanced Zio long-term continuous monitoring (LTCM) service to enhance the cardiac monitoring experience for patients and healthcare providers, together with new service enhancements. It is based on an AI algorithm that supports the capture and analysis of ECG data.

Therapeutic Drugs Hold the Largest Canine Dilated Cardiomyopathy Drugs Market Share

Therapeutic drugs hold the largest market share as they are necessary to manage life-threatening diseases by controlling symptoms and disease progression. These include positive inotropes such as pimobendane, ACE inhibitors, beta-blockers and diuretics, which form the basis of any treatment protocol to improve cardiac function, decrease fluid retention, and ultimately improve the quality of life of affected dogs. With the increasing diagnostic rate of DCM being partly due to increased awareness and the ability to perform advanced veterinary diagnostics, the need for well-established drug therapies is likely to increase.

For instance, in May 2024, UpCard-CA1 drugs, the first torsemide oral solution for dogs, received approval from the FDA, which is a concurrent therapy to be used for pulmonary edema in dogs with congestive heart failure secondary to myxomatous mitral valve disease (MMVD).

North America Dominates the Global Canine DCM Drugs Market Size

The North America region holds the primary position in the canine dilated cardiomyopathy (DCM) drugs market, owing to elevated veterinary care expenditures, established medical facilities, and innovative pharmaceutical research. The rising trend of humanizing pets leads to an increase in market demand owing as numerous pet owners select specialized treatments for conditions such as DCM. Through advanced veterinary systems, which include specialized hospitals and board-certified cardiologists, the diagnosis and treatment of veterinary patients are supported. Animal health companies that lead the industry dedicate significant resources to research and development to develop innovative cardiac medications. The combined effects of these elements result in North America becoming the main market for DCM drug sales worldwide.

Additionally, to oversee the growing pet humanization trends in this region organization also provides pet health insurance across Canada and the United States. For instance, in April 2025, the National American Pet Health Insurance Association, Inc. (NAPHIA) released its survey result, which shows that about 7.03 million pets were insured in North America at the end of 2024.

Impact of U.S. Tariffs on Global Canine Dilated Cardiomyopathy Drugs Market

US tariffs have the potential to affect the global canine dilated cardiomyopathy (DCM) drugs market by raising costs and impacting different supply chains. Most veterinary pharmaceuticals (as well as DCM drugs) are produced using foreign active pharmaceutical ingredients (APIs) and resources. Tariffs imposed on imported APIs increase the production costs of the manufacturer, that usually passed on to the veterinary clinics and pet owners, resulting in higher prices for the DCM treatment drugs. Some pet owners may delay treatment or not have the ability to afford the treatment, which could negatively impact animal welfare and demand for the products. Tariffs may also force companies to search for alternative suppliers, which may take time to locate or produce a delay or disruption in the product to the marketplace due to disrupted supply chains.

Key Players Landscape and Outlook

Continuous innovation and constant change promote the global canine dilated cardiomyopathy drugs market. Companies are investing in research and development to target new canine heart diseases with more effective treatments. Companies intend to improve drug product development, treatment options, and the safety and efficacy of medication used in the treatment of canine DCM. Many drug companies are strategically aligning their product development and market strategies with greater demand around a companion animal emphasis of pet health and wellness. The presence of an additional online veterinary pharmacy and tele-veterinary service will also change how treatment is accessed in the current market and beyond.

For instance, in November 2024, Boehringer Ingelheim International GmbH introduced VETMEDIN Solution approved by Food and Drugs Administration (FDA) to manage congestive heart failure in dogs to increase the survival time and provide quality of life in dogs who are affected by MMVD (myxomatous mitral valve disease) or DCM (dilated cardiomyopathy).

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Therapeutic Approach
    • 5.2.1.1. Symptom Management Drugs
      • 5.2.1.1.1. Diuretics
      • 5.2.1.1.2. Vasodilators
    • 5.2.1.2. Disease-Modifying Drugs
      • 5.2.1.2.1. ACE Inhibitors
      • 5.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
      • 5.2.1.2.3. Pimobendan
    • 5.2.1.3. Supportive Care Agents
      • 5.2.1.3.1. Anti-Arrhythmics
      • 5.2.1.3.2. Cardiac Glycosides
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Injectable
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Veterinary Hospitals
    • 5.2.3.2. Veterinary Clinics
    • 5.2.3.3. Retail Pharmacies
    • 5.2.3.4. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Therapeutic Approach
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Therapeutic Approach
    • 6.2.1.1. Symptom Management Drugs
      • 6.2.1.1.1. Diuretics
      • 6.2.1.1.2. Vasodilators
    • 6.2.1.2. Disease-Modifying Drugs
      • 6.2.1.2.1. ACE Inhibitors
      • 6.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
      • 6.2.1.2.3. Pimobendan
    • 6.2.1.3. Supportive Care Agents
      • 6.2.1.3.1. Anti-Arrhythmics
      • 6.2.1.3.2. Cardiac Glycosides
  • 6.2.2. By Route of Administration
    • 6.2.2.1. Oral
    • 6.2.2.2. Injectable
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Veterinary Hospitals
    • 6.2.3.2. Veterinary Clinics
    • 6.2.3.3. Retail Pharmacies
    • 6.2.3.4. Online Pharmacies
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Therapeutic Approach
        • 6.3.1.2.1.1. Symptom Management Drugs
        • 6.3.1.2.1.1.1. Diuretics
        • 6.3.1.2.1.1.2. Vasodilators
        • 6.3.1.2.1.2. Disease-Modifying Drugs
        • 6.3.1.2.1.2.1. ACE Inhibitors
        • 6.3.1.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
        • 6.3.1.2.1.2.3. Pimobendan
        • 6.3.1.2.1.3. Supportive Care Agents
        • 6.3.1.2.1.3.1. Anti-Arrhythmics
        • 6.3.1.2.1.3.2. Cardiac Glycosides
      • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.2.1. Oral
        • 6.3.1.2.2.2. Injectable
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Veterinary Hospitals
        • 6.3.1.2.3.2. Veterinary Clinics
        • 6.3.1.2.3.3. Retail Pharmacies
        • 6.3.1.2.3.4. Online Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Boehringer Ingelheim International GmbH
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Zoetis Inc.
  • 21.3.3. Merck & Co., Inc.
  • 21.3.4. Elanco Animal Health Incorporated
  • 21.3.5. Vetoquinol group
  • 21.3.6. Ceva Sante Animale
  • 21.3.7. Bayer AG
  • 21.3.8. Dechra Pharmaceuticals PLC
  • 21.3.9. Orion Corporation
  • 21.3.10. SAVA Vet

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer